Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction
Top Cited Papers
- 30 March 2010
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 121 (12), 1393-1405
- https://doi.org/10.1161/circulationaha.109.909614
Abstract
Background— The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF). The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial and to determine whether irbesartan altered the distribution of mode of death in HFPEF. Methods and Results— All deaths were reviewed by a clinical end-point committee, and the mode of death was assigned by consensus of the members. The annual mortality rate was 5.2% in the I-Preserve trial. There were no significant differences in mortality rate between the placebo and irbesartan groups. The mode of death was cardiovascular in 60% (including 26% sudden, 14% heart failure, 5% myocardial infarction, and 9% stroke), noncardiovascular in 30%, and unknown in 10%. There were no differences in the distribution of mode-specific mortality rates between placebo and irbesartan. Conclusions— Sixty percent of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure death being the most common. Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.This publication has 57 references indexed in Scilit:
- Death and Dying in Heart Failure With Normal Ejection FractionThe American Journal of Cardiology, 2009
- Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection FractionCirculation, 2009
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in AdultsCirculation, 2009
- Patterns of Structural and Functional Remodeling of the Left Ventricle in Chronic Heart FailureThe American Journal of Cardiology, 2008
- Death in Heart FailureCirculation: Heart Failure, 2008
- Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, MinnesotaCirculation, 2007
- Effects of Digoxin on Morbidity and Mortality in Diastolic Heart FailureCirculation, 2006
- Effect of amlodipine on mode of death among patients with advanced heart failure in the praise trialThe American Journal of Cardiology, 1998
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureThe New England Journal of Medicine, 1996
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureThe New England Journal of Medicine, 1986